RWA Wealth Partners LLC Acquires 18,027 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

RWA Wealth Partners LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4,518.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,426 shares of the biopharmaceutical company’s stock after buying an additional 18,027 shares during the period. RWA Wealth Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $13,125,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. Norges Bank bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $802,036,000. Amundi increased its position in Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Loomis Sayles & Co. L P raised its holdings in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after purchasing an additional 393,997 shares during the last quarter. Proficio Capital Partners LLC lifted its position in Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after purchasing an additional 219,162 shares during the period. Finally, Worldquant Millennium Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $127,489,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on REGN. TD Cowen lowered their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Sanford C. Bernstein reduced their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $637.36 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $629.02 and a 52-week high of $1,211.20. The company has a market cap of $69.68 billion, a P/E ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock’s 50-day simple moving average is $683.88 and its 200 day simple moving average is $797.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the business posted $11.86 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.